AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04318197 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Global rehabilitation program
Description: Patient with knee arthroplasty indication. After clinical assessment and a MRI measurement of muscle volume, patient start a 2 hours daily rehabilitation targeting muscles groups with strengthening and stretching exercises, 3 days per week during 4 weeks.
Study NCT02745288 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: inferior alveolar nerve block
Description: A long acting local anaesthetic agent Inj Bupivacaine hydrochloride 0.5% (2 ml) will be given after induction by open mouth technique by landmark method.~The mucobuccal fold will be palpated and traced till coronoid notch. The finger will be moved medially across the retromandibular trigone on internal oblique ridge. The 25G needle will be inserted till bone is felt. 2 ml of 0.5% bupivacaine will be injected slowly after withdrawing needle by 1mm and confirming negative aspiration of blood.
Study NCT02903979 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HVGIC
Description: In experimental group, the researches will be performed a restoration, after partial caries removal, with high viscosity glass ionomer cement in the teeth with deep caries lesion.
Study NCT02903979 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Indirect pulp capping
Description: In control group, the researches will be performed a indirect pulp capping with calcium hydroxide cement and high viscosity glass ionomer cement in the teeth with deep caries lesion.
Study NCT03361046 — intervention group
Intervention type: DEVICE
Intervention: Transcatheter Aortic Valve-in-Valve Implantation (ViV-TAVI)
Description: Patients with failed aortic valve bioprostheses qualified for TAVI due to coexisting illnesses
Study NCT04009616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aloe Vera mouthwash
Description: rinsing with aloe vera mouthwash for 5 days.
Study NCT04009616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthwash
Description: rinsing with chlorhexidine mouthwash for 5 days.
Study NCT04199832 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Dietary guidance
Description: Dietary guidance for feeding tube patients with food homogenate，dietary guidance for patients with oral feeding.
Study NCT04009616 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo mouthwash
Description: rinsing with placebo mouthwash for 5 days.
Study NCT04330872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enteric Coated Aspirin Tablet
Description: Study participants will be assigned to receive either EC Aspirin and will be required to continue taking them throughout the study (three days).
Study NCT04330872 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Plain Aspirin
Description: Study participants will be assigned to receive either Plain Aspirin and will be required to continue taking them throughout the study (three days).
Study NCT02606812 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Traditional-food
Description: Intake of ethnic local food
Study NCT04259333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib 200mg
Description: Celecoxib tablet
Study NCT04259333 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen, Codeine Drug Combination
Description: acetaminophen-codeine-caffeine tablet
Study NCT04571593 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Nidra
Description: The practice of Yoga Nidra, is a scripted and reproducible, guided meditation technique that promotes mental, emotional and physical relaxation while also facilitating the transition between waking and sleeping.
Study NCT01543165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac and nefopam balanced analgesia
Description: Sequential intravenous administration of ketorolac and nefopam
Study NCT04434573 — intervention group
Intervention type: OTHER
Intervention: Observation study
Description: French-speaking digestive surgeons are invited to respond to an online survey consisting of 13 common clinical situations concerning primary or asymptomatic incisional hernia pathology where a therapeutic decision is requested.
Study NCT01543165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Balanced analgesia using ketorolac and morphine
Description: Sequential intravenous administration of ketorolac and morphine
Study NCT01543165 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pain control with single analgesics (ketorolac)
Description: This arm do not use balanced analgesia. Instead, ketorolac IV administration followed by 50cc normal saline administration (for blinding) will be used in this group.
Study NCT02765035 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-Leg 4
Description: Microprocessor Controlled Knee
Study NCT02765035 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-Leg 3
Description: Microprocessor Controlled Knee
Study NCT02461784 — intervention group
Intervention type: PROCEDURE
Intervention: Semen & Data Collection
Description: If participants decide to participate in this research they will be asked to complete the informed consent process as well as asked a few questions such as age and race/ethnicity. If participants volunteered for this study because tehy have IBD, investigators will also collect some information from the participants medical record. Completing this portion of participation will take less than 1 hour.~Participants will then be scheduled to complete the semen collection at the UW Health Generations Fertility Clinic located at 2365 Deming Way in Middleton, WI. This collection visit will take less than 1 hour to complete. Once participants have finished the collection visit they will have completed their participation in this research project.
Study NCT04670939 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: breath exercises
Description: diaphragmatic breathing exercise that used during weaning is the respiratory physiotherapy
Study NCT00421954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Description: subjects will use ziprasidone
Study NCT00677716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 131I-chTNT-1/B MAb (Cotara)
Description: Given as a single interstitial infusion over approximately 25 hours at a dose of 2.5 mCi/cc.
Study NCT00927030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: supplemental liquid melatonin
Description: Liquid melatonin will be given to the parent. There are 4 dose levels (1mg, 3mg, 6 mg, and 9mg)of melatonin that will be used at 3 week intervals. The child will start with 1mg and the dose will be increased at 3 week intervals until the child is falling asleep within 30 minutes of bedtime on 5/7 nights per week. Once this goal is reached the child will stay on that dose through the remainder of the study.
Study NCT00927030 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: flavored liquid or liquid supplemental melatonin
Description: Single blind for parents at initial 3-weeks dose period of 1 mg melatonin for 18 children where 3/18 children will receive placebo and 15/18 children will receive melatonin study drug. Each bottle will be labeled as: Flavored liquid placebo/or liquid melatonin. After this initial 3-week period all children will receive known melatonin in bottles that state this.
Study NCT03095001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 5mg/kg intraperitoneal administration every 3 weeks for 4-6 cycles
Study NCT03095001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: carboplatin AUC=5 intraperitoneal administration every 3 weeks 4-6 cycles
Study NCT03095001 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: carboplatin AUC=5 intraperitoneal administration every 3 weeks 4-6 cycles
Study NCT03095001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: paclitaxel 175mg/m2, iv d1, every 3 weeks for 4-6 cycles
Study NCT02301455 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text messaging
Description: persistently hypertensive participants will be randomized to receive these tailored, motivational text messages
Study NCT04530071 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CordSTEM-DD (0.7 x 10^7 cells)
Description: CordSTEM-DD (0.7 x 10\^7 cells)
Study NCT04530071 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CordSTEM-DD (2.1 x 10^7 cells)
Description: CordSTEM-DD (2.1 x 10\^7 cells)
Study NCT03095001 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: paclitaxel 175mg/m2, iv d1, every 3 weeks for 4-6 cycles
Study NCT01487447 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Customized sound
Description: treatment with customized sound therapy
Study NCT01487447 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular Masker
Description: treatment with white noise
Study NCT04530071 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: HA + saline + placebo comparator
Study NCT00761098 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Standard Care: 25% salt poor albumin administered day 1 (1.5g/kg) and day 3 (1.0g/kg)
Study NCT02632526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5718 oral suspension crystalline form (1 to 100 mg/mL) (Part A)
Description: Oral suspension single dose
Study NCT02632526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5718 oral suspension amorphous (1 to 100 mg/mL) (Part A)
Description: Single and multiple doses
Study NCT02632526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5718 placebo oral suspension
Description: Single and multiple doses
Study NCT02632526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5718 oral suspension amorphous (1 to 100 mg/mL) (Part B)
Description: Single and multiple doses
Study NCT01060579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-12286 0.5% ophthalmic solution
Description: q.d. PM
Study NCT01060579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-12286 0.25% Ophthalmic solution
Description: q.d. PM
Study NCT01060579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost ophthalmic solution
Description: q.d. PM
Study NCT02135354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: * From day 1 up to and including day 3: 500 mg azithromycin PO once a day~* From day 4 up to and including day 90: 250 mg azithromycin PO once every 2 days
Study NCT02135354 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * From day 1 up to and including day 3: 500 mg placebo PO once a day~* From day 4 up to and including day 90: 250 mg placebo PO once every 2 days
Study NCT00761098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental
Description: 25% Salt Poor Albumin administered per standard care on day 1 (1.5g/kg). Second dose administered on day 2 only to those individuals with renal insufficiency and risk for renal failure.
Study NCT04782141 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hand motor coordination in a sitting positin
Description: The subject sat on the therapeutic table (without back support), feet resting on the floor. The upper limb was examined in adduction, with the elbow bent in the intermediate position between pronation and supination of the forearm. Wrist and a hand free from stabilization.
Study NCT04782141 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hand motor coordination in a supine position with the upper extremity positioned perpendicularly to the trunk
Description: motor tasks carried out in starting positions: supine with the upper extremity positioned perpendicularly to the trunk; the upper limb in adduction and flexion in the humeral joint, elbow extension, forearm in the intermediate position; elbow, wrist, hand free from stabilization.
Study NCT04782141 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hand motor coordination in a supine position with adduction in the humeral joint, elbow flexion in the intermediate position
Description: In the supine position, the upper limb was held beside the subject's body (adduction in the humeral joint, elbow flexion in the intermediate position between pronation and supination of the forearm. Wrist and a hand free from stabilization.
Study NCT01812187 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SHIFT Cognitive Behavioral Therapy
Description: Manualized, evidence-based, cognitive behavioral therapy for the treatment of substance abuse disorders
Study NCT01189448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyrimethamine/Sulfadiazine
Description: Pyrimethamine + sulfadiazine group : Pyrimethamine 50 mg once daily orally and sulfadiazine 1g tid. orally, with supplemental folinic acid 50 mg once a week.~Follow-up includes clinical and biological tolerance, according to usual recommendations. Monthly fetal ultrasound is performed. Prenatal diagnosis with amniocentesis is offered after 18 weeks gestation, usually 4 weeks after the maternal infection.~Treatment is be stopped or changed in case of toxicity. If prenatal diagnosis shows fetal infection with T. gondii, management is to be determined by the clinicians with the patient. If the prenatal diagnosis is negative the treatment can be stopped in order to reduce the risk of intolerance, providing that the mother receives at least 4 weeks of therapy.
Study NCT01189448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spiramycine
Description: Spiramycin group : spiramycin 1g tid orally Follow-up includes clinical and biological tolerance, according to usual recommendations. Monthly fetal ultrasound is performed. Prenatal diagnosis with amniocentesis is offered after 18 weeks gestation, usually 4 weeks after the maternal infection.~Treatment is be stopped or changed in case of toxicity. If prenatal diagnosis shows fetal infection with T. gondii, management is to be determined by the clinicians with the patient. If the prenatal diagnosis is negative the treatment is continued according to usual procedures
Study NCT02549196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Donepezil dose increased at weekly intervals up to first intolerable dose (FID) or to maximum allowed dose (MAD) together with solifenacin.
Study NCT02730962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Vancomycin 3 times a day for 7 days
Study NCT02730962 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pills identical in appearance to each antibiotics to be taken on the same schedule as each antibiotic
Study NCT02730962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neomycin
Description: Neomycin 3 times a day for 1 day
Study NCT02549196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin
Description: Donepezil dose increased at weekly intervals up to first intolerable dose (FID) or to maximum allowed dose (MAD) together with solifenacin.
Study NCT02730962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin
Description: Clindamycin 3 times a day for 5 days
Study NCT02730962 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: FMT conducted via colonoscopy
Study NCT02730962 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Fecal Microbiota Transplantation
Description: FMT conducted via colonoscopy
Study NCT00988338 — intervention group
Intervention type: BIOLOGICAL
Intervention: Trinity Evolution
Description: Novel Allogeneic, Cancellous, Bone Matrix Containing Viable Stem and Osteoprogenitor Cells
Study NCT00677638 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ventor Embracer
Description: Implantation of Ventor Embracer
Study NCT01612013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium bicarbonate plus saline
Description: Sodium bicarbonate solution (Sodium bicarbonate 8.4%, Equiplex, Brazil) was given by adding fifteen ampoules of sodium bicarbonate (150 mEq of sodium) to 1 L of 5% dextrose. Infusion in bolus began 60 min prior to the start of contrast administration at 3.5 ml/Kg/h, decreased to 1.18 ml/Kg/h during the contrast exposure and for the next 6 hours after the procedure. Saline (0.9 percent) was given IV at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
Study NCT01612013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous NAC plus saline
Description: Acetylcysteine (Flucistein 100 mg/ml, Neo Química, Brazil) was given via IV bolus at a rate of 150 mg/kg in 500 ml dextrose 5% over 60 min immediately before contrast exposure and followed by 50 mg/kg in 500 ml dextrose 5% during the contrast exposure and for 6 hours after the procedure. Saline (0.9 percent) was given IV at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
Study NCT00543374 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00543374 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PROCHYMAL adult human mesenchymal stem cells
Description: intravenous infusion four times over two weeks; possibly repeated once
Study NCT06140654 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical oral examination
Description: Clinical oral examinations are conducted by a dental practitioner. They point out the number of teeth (ranging from 0 to 32), the number of occlusal functional units (OFU, ranging from 0 to 10, with one unit considered as a pair of antagonist premolars and molars that had at least one contact area during maximum intercuspal relationships, evaluated by asking the participants to clench on a 200 µm thick articulating paper, the presence of dental prostheses (fixed prosthesis and removable denture), the number of denture worn during meals (removable partial or complete denture, either maxillary or mandibular, or both, with number ranging from 0 to 2), the number of decayed, missing, filled teeth (DMFT index, based on 28 teeth), and the Russel's periodontal index which is presently preferred to the Community (namely CPITN) because it takes tooth mobility into account.
Study NCT01612013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NAC plus sodium bicarbonate plus saline
Description: Acetylcysteine was given intravenous at a rate of 150 mg/kg over 60 min before contrast exposure and followed by 50 mg/kg during the contrast exposure and for 6 hours after the procedure. Sodium bicarbonate solution(150 mEq of sodium) was began 60 min prior to the start of contrast administration at 3.5 ml/Kg/h, decreased to 1.18 ml/Kg/h during the contrast exposure and for the next 6 hours after the procedure. Saline was given intravenous at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
Study NCT06140654 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Food behavior
Description: Food selective behavior is assessed using a food selectivity questionnaire previously developed for French adults 34. Participants will be interviewed and asked to check each food item they do not eat among a list of 71 familiar products which includes raw foods and dishes from the following categories: starters, meat, fish, egg, garnish, dairy products, desserts, bread, and beverages. A food selectivity score corresponding to the total number of avoided foods will be assessed for each participant. For each avoided food, participants explain why they do not eat it among reasons including I don't know it, I dislike it, I suffer from chewing or swallowing it (oral discomfort), I experience difficulties digesting the food, This food is forbidden for medical reason, and This food is forbidden for ethical or religious reasons.
Study NCT02518789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose Dexmedetomidine
Description: Pretreatment：Intravenous injection dexmedetomidine 0.5 µg/kg ，completed within 15 minutes.
Study NCT02518789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose dexmedetomidine
Description: Pretreatment：Intravenous injection dexmedetomidine 1 µg/kg ，completed within 15 minutes.
Study NCT02518789 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Pretreatment：Intravenous injection normal saline equal quantity，completed within 15 minutes.
Study NCT02518789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etomidate
Description: After 90 seconds of Pretreatment，intravenous infusion of etomidate fat emulsion 0.3mg/kg.~-Does not offer any other drugs within 5 min after completion of etomidate.
Study NCT02518789 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Etomidate
Description: After 90 seconds of Pretreatment，intravenous infusion of etomidate fat emulsion 0.3mg/kg.~-Does not offer any other drugs within 5 min after completion of etomidate.
Study NCT02518789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam，fentanyl，rocuronium
Description: Anesthesia induction：Intravenous injection midazolam 0.03 \~ 0.05 mg/kg, fentanyl 5 \~ 8 g/kg, rocuronium 0.6 mg/kg
Study NCT02518789 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: midazolam，fentanyl，rocuronium
Description: Anesthesia induction：Intravenous injection midazolam 0.03 \~ 0.05 mg/kg, fentanyl 5 \~ 8 g/kg, rocuronium 0.6 mg/kg